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ABSTRACT 
In pharmaceutical industry, the sponsors are interested in bringing their drug products from one region (e.g., the United Sta tes of America) to 
another region (e.g., Asian Pacific) to increase the exclusivity of the drug products in the marketplace. However, it is about the clinical results 
that can be extended from the victim patient population in one region to a similar, but different patient population in a new region due to a 
possible difference in ethnic factors. The International Conference on Harmonization (ICH) suggested that a bridging study may be important to 
extrapolate the clinical results between regions. However, little or no information concerns the basis for determining whether a bridging study 
is necessary based on the assessment of the complete clinical data package provided by the ICH. Moreover no criteria on the evaluation of 
similarity of clinical results between regions is given.  
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INTRODUCTION 
International development of pharmaceutical products has 
become the key to the favorable result of any pharmaceutical 
sponsors. It is therefore key to address the efficacy and 
safety difference of a new test pharmaceutical product 
among different geographic regions due to ethnic factors. 
For any marketing acceptance of pharmaceutical product in 
new region, sponsors are required to provide a considerable 
evidence of effectiveness and safety from sufficient and well 
controlled clinical trials. So, a bridging study is involved 
which is a supplementary study on a particular medicine 
that is performed in new region. Bridging studies mainly 
focuses on the effectiveness , safety and dose response of 
new drugs, that could provide an additional drug response 
data in the population of new region. However, after the 
pharmaceutical product is approved by the original region 
such as the united states or European union, sponsors might 
seek the registration of the product in the new region. Due to 
the possible differences on ethnicity and clinical practice of 
the new region, the concerns that these differences may 
have an impact on the safety, efficacy, dose, and dosing 
regimen that have limited willingness for the regulatory 
authority in the new region. Recently, geotherapeutics has 
attracted much attention from sponsors as well as 
regulatory authorities from different geographic regions. To 
address this issue, the international conference on 
harmonization(ICH) has published a guideline is titled 
“Ethnic factors in the acceptability of foreign clinical data”, 
which is known as ICH E5 guideline. 
According to the ICH E5 guidance, ethnic factors are factors 
are associated with races or larger populations grouped 
according to common trails and customs which they mainly 
focus on pharmacodynamics and pharmacokinetic 
properties. Ethnic factors may be categorize intrinsic or 
extrinsic. Intrinsic ethnic factors are factors which include 
genetic polymorphism, age, height, gender, weight, lean body 
mass, body composition, and organ dis-function. Whereas 
extrinsic factors include social and cultural aspects of region, 
such as medical practices, diet, use of tobacco, use of alcohol 
and compliance with prescribed medications, particularly 
important are the reliance on studies from a different region, 
practices in clinical trials, design and conduct. A bridging 
study therefore can be done at the beginning, during or at 
the end of a global development programme. ICH E5 also 
contains a bridge data package of selected information from 
the complete clinical data package (CCDP), which is relevant 
to the population of the new region. 
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NATURE AND TYPES OF BRIDGING STUDIES 
This guidance implemented when the regulatory authority 
of the new region is presented with a clinical data package to 
achieve its regulatory requirements, the authority should 
request only those additional data necessary to assess the 
ability to extend the foreign data from the Complete Clinical 
Data Package to the new region. The quality of the medicine 
to ethnic factors will help to control the amount of such data. 
In most cases, a single trial that accomplished to provides 
these data in the new region and confirms the capability to 
extended data from the original region should enough and 
should not need further replication. Note that even though a 
single study should be sufficient to “bridge” efficacy data, a 
sponsor may find it practical to obtain the necessary data by 
managing more than one study. From the ICH E5 guidance 
the following tabled explains the types of bridging studies by 
controlled clinical trials (Table 1).
 
Table :1 Controlled clinical trails 
Medicine Region Medical 
practices 
Drug class Clinical 
experience 
Bridging 
studies 
Insensitive - Similar - - No 
Sensitive Similar - - Sufficient No 
Sensitive Dissimilar Similar Familiar - No 
Dosage - Different Unfamiliar Insufficient CCDP 
 
The population between two regions are similar and their 
clinical trials are also similar and medical trails are done 
equally for both regions and the variation between two 
regions are shown in the table 1. If the medicine is 
insensitive and medical practices are similar in both the 
regions and the drug class is familiar one in the region, then 
it is controlled pharmacodynamic (PD) study with a well 
established pharmacological end point may generate the 
necessary data to bridge the foreign clinical data. However 
the medicine is sensitive and it is done in similar regions 
with sufficient clinical experience without any study of 
bridging studies, then it is controlled by a pharmacokinetic 
(PK),the general relationship between PK,PK/PD and clinical 
studies are indefinite. The similarity observed from PK 
studies to reproducibility in clinical trials requires further 
research. The type of research can start by examining 
systematically the relationship among PK,PD, and clinical 
data of approved drugs by drug class. 
Extrapolation and similarities: 
ICH E5 clearly states that assessment of ability to 
extrapolate foreign data depends upon similarity of dose 
response efficacy &safety between new and original regions. 
The treatment effect for region is defined as 
(∆1=µT-µ1p1  I=01µ) 
Let YJK be some efficacy response variable for patient k 
receiving treatment j in region I,k=….k;j=T(test),p 
I=0(original) N(new). 
The concept of positive treatment effect is defined as the 
medicine has already been approved in original region due 
to its efficacy placebo control in some new region data is 
collected from bridging studies .The new region 
demonstrate superior efficacy test medicine over test 
medicine over placebo control the effect from similarity can 
be educated through the following hypothesis. 
H0=∆N<0 vs Ha:∆N>0….(1) 
The positive treatment effect does not really gives the 
similarity of the magnitude of efficacy between two regions 
bio equivalence to evaluation of similarity of extrapolation of 
foreign clinical data relationship between ծ and overall 
treatment effect ∆ can be expressed as ծ=f∆, ծ is clinically 
acceptable and meaningful only if 0<f<1 because similarity 
dictates that the difference of treatment effect. 
Let Ɵ=(µNT-µNP)-(µOT-µOP) the corresponding hypothesis can 
be formulate as following two sided equivalence hypothesis. 
[H0=Ɵ<-ծ or Ɵ>ծ vs Ha:<Ɵ<ծ]…(2) 
The non-linearity test may also appropriate for evaluation of 
the difference between two regions that are evaluated the 
one region has similar it and the new region doesn’t have 
any similarity in efficacy .The one sided non inferiority 
hypothesis is given as. 
[Hα:Ɵ<-ծ vs Ha:Ɵ> -ծ]…(3) 
ShiH proposed the idea of consistency for evaluation of the 
similarity of the efficacy between the new and original 
region, Let w=(w1….wN) be the result of the H reference 
studies that were conducted in the original region and let v 
be the result of the bridging study is said to be constant with 
the previous result w if 
P(v/w)> min {p(wn/w)h=1…..H}…(4) 
When P(u/w) is the productive probability function of the 
study U given the previous result W the concept of 
consistency in eq :4 can be reformulated. 
|∆N-∆|<V….(5) 
Where ∆ is the mean of treatment effect over the H previous 
studies under the normal assumption. 
V2=max [(∆h-∆1)2h=1…H] 
CONCLUSION 
For the pharmaceutical product before being marketed need 
to be evaluated for means of product safety efficacy and 
potency by the guidance of various regulatory bodies and 
other guidelines for performing clinical trials to determine 
&ensure the product. The ICH E5guidelines provides 
information regarding clinical trials and the acceptance 
criteria for the pharmaceutical product like safety efficacy 
and quality this intern follows various evaluation and 
analytical methods that describes the product properties 
and its acceptance into the market during the investigational 
studies of pharmaceutical products. 
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